Author: Keating, Sheila M.; Mizrahi, Rena A.; Adams, Matthew S.; Asensio, Michael A.; Benzie, Emily; Carter, Kyle P.; Chiang, Yao; Edgar, Robert C.; Gautam, Bishal K.; Gras, Ashley; Leong, Jackson; Leong, Renee; Wearn Lim, Yoong; Manickam, Vishal A.; Medina-Cucurella, Angelica V.; Niedecken, Ariel R.; Saini, Jasmeen; Fredrik Simons, Jan; Spindler, Matthew J.; Stadtmiller, Kacy; Tinsley, Brendan; Wagner, Ellen K.; Wayham, Nicholas; Tracy, LaRee; Vingsbo Lundberg, Carina; Büscher, Dirk; Vicente Terencio, Jose; Roalfe, Lucy; Pearce, Emma; Richardson, Hayley; Goldblatt, David; Ramjag, Anushka T.; Carrington, Christine V.F.; Simmons, Graham; Muench, Marcus O.; Chamow, Steven M.; Monroe, Bryan; Olson, Charles; Oguin, Thomas H.; Lynch, Heather; Jeanfreau, Robert; Mosher, Rachel A.; Walch, Matthew J.; Bartley, Christopher R.; Ross, Carl A.; Meyer, Everett H.; Adler, Adam S.; Johnson, David S.
Title: Generation of recombinant hyperimmune globulins from diverse B-cell repertoires Cord-id: jbhchemt Document date: 2021_4_15
ID: jbhchemt
Snippet: Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply, and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent hyperimmune globulins. Our method generates thousands-diverse mixtures of recombinant antibodies, enriched for specificity and activity against therapeu
Document: Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply, and batch-to-batch variation. Here we describe a microfluidics and molecular genomics strategy for capturing diverse mammalian antibody repertoires to create recombinant multivalent hyperimmune globulins. Our method generates thousands-diverse mixtures of recombinant antibodies, enriched for specificity and activity against therapeutic targets. Each hyperimmune globulin product comprised thousands to tens of thousands of antibodies derived from convalescent or vaccinated human donors, or immunized mice. Using this approach, we generated hyperimmune globulins with potent neutralizing activity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in under three months, Fc-engineered hyperimmune globulins specific for Zika virus that lacked antibody-dependent enhancement of disease, and hyperimmune globulins specific for lung pathogens present in patients with primary immune deficiency. To address the limitations of rabbit-derived anti-thymocyte globulin (ATG), we generated a recombinant human version and demonstrated its efficacy in mice against graft-versus-host disease.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date